Cannabidiol (CBD) (INN) is one of at least 113 active cannabinoids identified in cannabis. It is a major phytocannabinoid, accounting for up to 40% of the plant’s extract. CBD is considered to have a wide scope of potential medical applications - due to clinical reports showing the lack of side effects, particularly a lack of psychoactivity (as is typically associated with ∆9-THC).
- government licensed operation
- all products are made from legal EU hemp varieties
- a guarantee of natural phytocannabinoid content
2017: Cannabidiol reduces neuroinflammation and promotes neuroplasticity and functional recovery after brain ischemia
Collectively, the present results demonstrate that short-term CBD treatment results in global functional recovery in ischemic mice and impacts multiple and distinct targets involved in the pathophysiology of brain ischemic injury.